Salute e Benessere

MolecuLight's Pioneering Fluorescence Imaging Technology Showcased in…

Key findings from the study include: Key findings from the study include: "These compelling results underscore the transformative impact of MolecuLight in burn wound management – yet another area of wound care where our technology drives change," said Anil Amlani, CEO at MolecuLight Inc. "By providing clinicians with real-time, objective data on bacterial presence, MolecuLight's fluorescence imaging technology empowers them to make more informed decisions, ultimately leading to…
PR Newswire
30/05/2024

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic…

SLE is a chronic autoimmune disease causing widespread inflammation and tissue damage in the affected organs. There are about one million SLE patients in China, ranking the first worldwide in total numbers and the second in incidence rate. Current conventional therapies include corticosteroids, antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), cytotoxic drugs and immunosuppressive/modulatory agents. However, conventional treatments are poorly tolerated over time, which affects…
PR Newswire
30/05/2024

Illusion Aligners Makes Record-Breaking Achievement with its Biggest Aligner in…

This Biggest Aligner holds impressive dimensions of 1900 mm (about 6.23 ft) in width and 1650 mm (about 5.41 ft) in height and was crafted meticulously using Taglus PETG material. This creation was carefully crafted in a diligent eight-step process, beginning with impression collection, pouring, and 3D model printing, followed by thermoforming and precise laser marking. It then underwent thorough finishing, polishing, and quality checking before being keenly packed. It was officially recorded on…
PR Newswire
30/05/2024

Ischemic Heart Disease (IHD) Drugs Market Worth USD 8.46 Billion to 2031 -…

Ischemic heart disease drug treatments focus on returning the heart's blood flow to a normal state, which is frequently impaired due to narrowed or blocked coronary arteries. The heart can work better and have fewer heart attacks with the help of some medications. Ischemic heart disease drug treatments focus on returning the heart's blood flow to a normal state, which is frequently impaired due to narrowed or blocked coronary arteries. The heart can work better and have fewer heart attacks…
PR Newswire
30/05/2024

Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034 |…

Key Takeaways from the Stuttering Market Report Key Takeaways from the Stuttering Market Report Discover which therapies are expected to grab the major stuttering market share @Stuttering Market Report Stuttering Overview Childhood-onset fluency disorder, commonly referred to as stuttering or stammering, is a prevalent speech issue influenced by various factors. It results in an interruption of smooth verbal expression, characterized by involuntary repetitions or...
PR Newswire
30/05/2024

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and…

Clinical study performed in 2022 now published in peer-reviewedNeurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum®Early onset can be expected thanks to early blood concentration of midazolam with ZEPIZURE®Low variability confirmed, a key advantage vs other forms of administration, such as intranasal Dijon, France May 30, 2024 -1030 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in...
Nasdaq GlobeNewswire
30/05/2024

Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01…

Arash Mostaghini, Associate Professor of Dermatology at Brigham & Women's Hospital, said, "These results are extremely encouraging. They validate the potential for STS-01 to provide mild-to- moderate alopecia sufferers with a safe and effective treatment for this debilitating condition. I am also excited by the prospect of targeting total hair regrowth in this patient group." Arash Mostaghini, Associate Professor of Dermatology at Brigham & Women's Hospital, said,"These…
PR Newswire
30/05/2024

Masan High-Tech Materials Group and Mitsubishi Materials Corporation Group…

Nyobolt is starting to scale and commercialize its operations. In July 2023, Nyobolt unveiled an EV concept with 6-minute charging time and has signed Head of Terms with two major commercial customers. There is monetary upside for Masan as Nyobolt starts to commercialize its innovative tungsten-niobium battery technology. Nyobolt is starting to scale and commercialize its operations. InJuly 2023, Nyobolt unveiled an EV concept with 6-minute charging time and has signed Head of Terms with two...
PR Newswire
30/05/2024

Tetra Pharm Technologies and Kvantify Announce Partnership to Accelerate the…

"We are proud to partner with Kvantify, a company that shares our passion for scientifically based technological solutions to real-world challenges. This partnership will expedite our drug development process and significantly expand our pipeline of promising drug candidates in 2024," says Martin Rose, Chief Executive Officer of Tetra Pharm Technologies. "We are proud to partner with Kvantify, a company that shares our passion for scientifically based technological solutions to…
PR Newswire
30/05/2024

Oculis Publishes Results of 2024 Annual General Meeting and Announces…

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRockOculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the...
Nasdaq GlobeNewswire
30/05/2024

NTC gives long term consistency to its ophtha portfolio with another MDR CE…

"To build a strong foundation and unleash sustainable growth in the future", states Riccardo Carbucicchio CEO of NTC, "we have proactively moved ahead already time ago and begun working towards meeting MDR requirements and obtaining CE marks renewals for our medical devices, according to the new EU regulation, before the deadlines. In this way, we have been trying and keep trying to secure our portfolio and give long term continuity to the agreements in place with our customers…
PR Newswire
30/05/2024

Vesper Bio announces completion of single ascending dose stage in trial of its…

Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement. Progranulin is a protein known to play a key role in promoting neuron survival, growth and function. People with FTD(GRN) have inherited gene mutations associated with low progranulin levels. Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement…
PR Newswire
30/05/2024

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative…

® (INN: Piflufolastat ( 18 F) also known as ( 18 F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen...
Nasdaq GlobeNewswire
30/05/2024

Statement of total voting rights and shares forming the company's share capital…

Article R. 22-10-23 of the French Commercial CodeMarket : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site :www.inventivapharma.comDateNumber of Shares Outstanding Total voting rights, gross(1) Total voting rights, net(2)May 13, 202452 477 18865 493 08165 381 630 (¹) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11...
Nasdaq GlobeNewswire
30/05/2024

Combined General Meeting of June 20, 2024 - Availability of the preparatory…

Daix (France), Long Island City (New York, United States), May 30, 2024– Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined...
Nasdaq GlobeNewswire
30/05/2024

SciBase receives first order in Austria

"It is pleasing to see that our strategy and belief in Nevisense is beginning to bear fruit. Joachim Kaiser, our sales representative in Austria, does a fantastic job and has managed to get a first sale in a short time. This strengthens our belief that Austria and Switzerland can develop into good markets for us," says Pia Renaudin CEO of SciBase. "It is pleasing to see that our strategy and belief in Nevisense is beginning to bear fruit.Joachim Kaiser, our sales representative…
PR Newswire
30/05/2024

Nanoform's biologics technology showcased by large pharma at drug delivery…

(Numbers in Brackets Refer to the Corresponding Last Year Reporting Period, Unless Otherwise Mentioned.) (Numbers in Brackets Refer to the Corresponding Last Year Reporting Period, Unless Otherwise Mentioned.) * Defined as materials & services expenses, employee benefit expenses, and other operating expenses. ** Including Treasury bills. Part of the cash has been invested in short-term government bonds. ***Cash position after the new share issue wasEUR 54.7 monApril 30, 2024...
PR Newswire
30/05/2024

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting is available on the Cellectis website:https://www.cellectis.com/en/investors/general-meetings/About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of...
Nasdaq GlobeNewswire
29/05/2024

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 Goldman Sachs 45 thAnnual Global Healthcare Conference onWednesday, June 12, 2024 Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq:...
PR Newswire
29/05/2024

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024. GENFIT accelerates its research in Acute on-Chronic Liver Failure (ACLF)EF CLIF and GENFIT partnership event GENFIT will co-host an event with the European...
Nasdaq GlobeNewswire
29/05/2024

Alkermes to Participate in Two Upcoming Investor Conferences

Goldman Sachs 45th Annual Global Healthcare ConferenceDate/Time:Tuesday, June 11, 2024 at 10:40 a.m. EDT (3:40 p.m. BST) Goldman Sachs 45 thAnnual Global Healthcare Conference Date/Time:Tuesday, June 11, 2024at10:40 a.m. EDT( 3:40 p.m. BST ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the...
PR Newswire
29/05/2024

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene…

Innovative cell therapy manufacturing platform moving industry toward widespread patient access to life-saving cell and gene therapies Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the commercial launch of IRO ®, a next-generation platform built specifically to overcome the current challenges in CGT manufacturing. The company today revealed the IRO platform at ISCT 2024 , International Society for Cell & Gene Therapy's...
Nasdaq GlobeNewswire
29/05/2024

AB Science provides an update on the application for conditional marketing…

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, 29 May, 2024, 6pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the...
Nasdaq GlobeNewswire
29/05/2024

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B in the attached file.Investor Relations Tobias Bjorklund+45 3077 8682 tobb@novonesis.com Anders Enevoldsen+45 5350 1453 ...
Nasdaq GlobeNewswire
29/05/2024
Altri  Comunicati